查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433586

美国癌症显影剂市场规模、份额和趋势分析报告：按类型、方式、应用和细分市场预测，2024-2030 年

U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report By Type, By Modality, By Application, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 94 Pages | 商品交期: 2-10个工作天内

价格

美国癌症显影剂市场的成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，美国癌症显影剂市场预计将达到15.3亿美元，2024年至2030年的复合年增长率为11.7%。

主要市场参与者之间不断加强的合作和伙伴关係、政府和私营部门研发投资的增加以及人工智慧在诊断成像中的整合正在增强造影显影剂的能力。因此，这些因素正在推动美国癌症显影剂市场的成长。

新产品的推出增加了製造商之间的竞争，促进创新，降低价格，并最终增加患者和医疗保健提供者的选择。整体市场扩张的潜力取决于新型显影剂的生产，这些造影剂可提供更高的安全性、增强的目标特异性和独特的成像特性。这为诊断和治疗开闢了新途径。例如，2023 年 4 月，GE Healthcare 透过向其 MRI 药物基本客群引入两种优质大环化合物 Clariscan（钆特酸）和 Pixoscan（钆布醇）扩大了造影显影剂范围。该行业的主要企业正在努力扩大产品系列，向市场推出新产品，并加强研发，从而推动市场成长。

此外，医疗保健预算的增加通常会鼓励公共卫生倡议，促进癌症的早期发现和改善先进诊断工具的取得。这些努力提高了人们对造影影像重要性的认识，并增加了对相应显影剂的需求。增加的医疗保健预算吸引了新进入者并激励现有相关人员参与市场竞争。这种动态刺激了创新，促进了价格竞争，并最终为医疗保健专业人员和患者提供了更多选择。这些倡议正在为市场扩张创造有利可图的机会。

美国癌症显影剂市场报告亮点

  • 由于医学影像诊断的增加，碘显影剂在该类型细分市场中占据主导地位，到 2023 年，其份额将达到 39.5%。
  • 预计放射性药物领域在预测期内将以最快的复合年增长率成长。
  • 核子医学影像领域在预测期内占据最大市场占有率，到 2023 年将达到 38.2%，因为它能够提供体内结构和功能的详细而准确的图像，从而为医疗保健专业人员提供准确的诊断。期间增长最快
  • 久坐的生活方式、吸烟率的增加和空气污染的加剧导緻美国癌症盛行率不断上升。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国癌症显影剂市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国癌症显影剂市场：法律规范、标准和合规性
  • 美国癌症显影剂市场：报销方案
  • 美国癌症显影剂市场：分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国癌症显影剂市场：类型估计和趋势分析

  • 类型市场占有率，2023 年和 2030 年
  • 细分仪表板
  • 美国癌症显影剂市场：按类型分類的前景

第五章美国癌症显影剂市场：模态估计与趋势分析

  • 2023年及2030年医疗器材市场占有率
  • 细分仪表板
  • 美国癌症显影剂市场前景：依方式分类

第六章美国癌症显影剂市场：应用预估及趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 美国癌症显影剂市场前景：依应用分类

第七章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Bayer AG
    • Lantheus
    • Bracco
    • Guerbet
    • Trivitron Healthcare
    • Cardinal Health
    • Telix Pharmaceuticals Limited
    • GE HealthCare
    • IMAX Diagnostic Imaging
    • Nano Therapeutics Pvt. Ltd.
Product Code: GVR-4-68040-184-8

U.S. Cancer Contrast Media Market Growth & Trends:

The U.S. cancer contrast media market is anticipated to reach USD 1.53 billion by 2030 and is anticipated to expand at a CAGR of 11.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing collaboration and partnerships among key market players, coupled with growing government and private sector R&D investments, alongside the integration of AI in diagnostic imaging enhance the capabilities of contrast media. Thus, these factors collectively propel the growth of U.S. cancer contrast media market.

Introducing new products can ignite positive competition among manufacturers, fostering innovation, lowering prices, and ultimately enhancing choices for both patients and healthcare providers. The potential for expanding the overall market depends upon the manufacturing of novel contrast agents that offer heightened safety, enhanced target specificity, or distinctive imaging properties. This opens up new pathways for both diagnosis and treatment. For instance, in April 2023 , GE Healthcare has broadened its range of contrast media by introducing two premier macrocyclic molecules, namely Clariscan (gadoteric acid) and Pixxoscan (gadobutrol), to its customer base for MRI agents. The industry key players are involved in enhancing R&D by introducing novel products to the market by expanding their product portfolio, which drives market growth.

Moreover, increased funding in healthcare budgets often facilitates public health initiatives promoting early cancer detection and enhanced accessibility to advanced diagnostic tools. These initiatives enhance awareness of the importance of contrast-enhanced imaging, consequently fueling demand for corresponding contrast media. The growth in healthcare budgets attracts new players and motivates existing stakeholders to compete in the market. This dynamic stimulates innovation, fosters price competitiveness, and ultimately leads to a broader range of options for both healthcare providers and patients. Such initiatives create a lucrative opportunity for market expansion.

U.S. Cancer Contrast Media Market Report Highlights:

  • Iodinated contrast media dominated the type segment with a share of 39.5% in 2023 owing to the increasing medical imaging procedures.
  • The radioactive agents segment is expected to grow at the fastest CAGR over the forecast period.
  • The nuclear imaging segment held the largest market share of 38.2% in 2023 and is anticipated to witness fastest growth over the forecast period owing to its ability to provide detailed and accurate images of internal structures and functions within the body which allows healthcare professionals for precise diagnosis.
  • Sedentary lifestyle, increasing incidences of smoking and rising air pollution are contributing to the growing prevalence of cancer cases in U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Modality
    • 1.2.3. Application
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Modality outlook
    • 2.2.3. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Cancer Contrast Media Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing number of clinical studies
      • 3.2.1.2. Rising cancer cases
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Side effects and adverse reactions related to contrast agents
      • 3.2.2.2. Presence of alternative imaging options
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Increasing demand for medical imaging
    • 3.2.4. Market challenges analysis
      • 3.2.4.1. Shortage of contrast media due to supply chain disruptions
  • 3.3. U.S. Cancer Contrast Media Market: Regulatory Framework and Standards & Compliances
  • 3.4. U.S. Cancer Contrast Media Market: Reimbursement Scenario
  • 3.5. U.S. Cancer Contrast Media Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. U.S. Cancer Contrast Media Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Cancer Contrast Media Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Gadolinium-based Contrast Media
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Iodinated Contrast Media
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Radioactive Agents
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Cancer Contrast Media Market: Modality Estimates & Trend Analysis

  • 5.1. Modality Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Cancer Contrast Media Market by Modality Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Nuclear Imaging
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. CT scans
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Mammography
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. MRI scans
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Ultrasound
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Cancer Contrast Media Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Cancer Contrast Media Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Breast Cancer
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Bladder Cancer
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Colorectal Cancer
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Lung Cancer
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Prostate Cancer
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Bayer AG
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Lantheus
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Bracco
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Guerbet
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Trivitron Healthcare
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Cardinal Health
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Telix Pharmaceuticals Limited
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. GE HealthCare
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. IMAX Diagnostic Imaging
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Nano Therapeutics Pvt. Ltd.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. cancer contrast media market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. cancer contrast media market, by modality, 2018 - 2030 (USD Million)
  • Table 4 U.S. cancer contrast media market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. cancer contrast media market: market outlook
  • Fig. 10 U.S. cancer contrast media competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. cancer contrast media market driver impact
  • Fig. 16 U.S. cancer contrast media market restraint impact
  • Fig. 17 U.S. cancer contrast media market strategic initiatives analysis
  • Fig. 18 U.S. cancer contrast media market: Type movement analysis
  • Fig. 19 U.S. cancer contrast media market: Type outlook and key takeaways
  • Fig. 20 Gadolinium-based contrast media market estimates and forecast, 2018 - 2030
  • Fig. 21 Iodinated contrast media estimates and forecast, 2018 - 2030
  • Fig. 22 Radioactive agents market estimates and forecast, 2018 - 2030
  • Fig. 23 Others estimates and forecast, 2018 - 2030
  • Fig. 24 U.S. cancer contrast media Market: Modality movement Analysis
  • Fig. 25 U.S. cancer contrast media market: Modality outlook and key takeaways
  • Fig. 26 Nuclear imaging market estimates and forecasts, 2018 - 2030
  • Fig. 27 CT scans market estimates and forecasts, 2018 - 2030
  • Fig. 28 Mammography market estimates and forecasts, 2018 - 2030
  • Fig. 29 MRI scans market estimates and forecasts, 2018 - 2030
  • Fig. 30 Ultrasound market estimates and forecasts, 2018 - 2030
  • Fig. 31 U.S. cancer contrast media market: Application movement analysis
  • Fig. 32 U.S. cancer contrast media market: Application outlook and key takeaways
  • Fig. 33 Colorectal cancer market estimates and forecasts, 2018 - 2030
  • Fig. 34 Bladder cancer market estimates and forecasts, 2018 - 2030
  • Fig. 35 Breast cancer market estimates and forecasts, 2018 - 2030
  • Fig. 36 Lung cancer market estimates and forecasts, 2018 - 2030
  • Fig. 37 Prostate cancer market estimates and forecasts, 2018 - 2030
  • Fig. 38 Other market estimates and forecasts, 2018 - 2030
  • Fig. 39 Market share of key market players - U.S. cancer contrast media market
  • Fig. 40 Key company categorization
  • Fig. 41 Company market positioning
  • Fig. 42 Key company market share analysis, 2023
  • Fig. 43 Strategic framework